Skip to main content

Rakesh Jhunjhunwala invested company under SFIO gaze over charges of cheating, diversion of funds

The corporate affairs ministry ordered a probe after RoC found that the company allegedly diverted Rs 1,000 crore and also failed to pay Rs 150 crore in interest.

The Ministry of Corporate Affairs (MCA) has ordered the Serious Fraud Investigation Office (SFIO) to investigate the charges of cheating and diversion of funds amounting to more than Rs 1,000 crore by Bilcare Ltd, a company in which ace Investor Rakesh Jhunjhunwala recently invested.

Bilcare was in the news recently after Jhunjhunwala made Rs 13 lakh daily from the stock in 69 sessions since March 23, 2020.

The Registrar of Companies (RoC) has already conducted one round of inquiry against the Pune-based company and submitted a report to the ministry.

“The RoC found that the company, in the last six years, has accepted deposits from public/shareholders amounting to about Rs 350 crore and failed to pay interest amount to the tune of about Rs 150 crore as on March 31, 2019, to thousands of deposit holders,” a source told Moneycontrol.


“The company has also diverted more than Rs 1,000 crore as investments, and loans and advances to foreign subsidiaries in Mauritius, Germany, Italy and Singapore. It has made investments amounting to about Rs 500 crore in wholly-owned subsidiaries like Bilcare Singapore Pte Limited. The entire amount was lost after the Singapore High Court ordered the liquidation of the subsidiary," the source said.

The RoC initiated the inquiry after receiving complaints from many deposit holders.

Confirming the SFIO probe, a source in the ministry said, "Continuing its action against companies which raise deposits from public and siphon off funds, the ministry has ordered an SFIO investigation into the affairs of Bilcare Ltd.”

Bilcare deals in pharma packaging solutions and clinical material supplies for new drug discovery projects.

Bilcare has been paying interest on time to all deposit holders, even during COVID-19, company sources said. “The company is responding to the letter from SFIO with appropriate advice from its advocates,” they said.

“Another observation in the RoC report is that the company has taken huge loans amounting to about Rs 714.37 crore from various banks from time to time and has defaulted on repayments. The company owes about Rs 2,000 crore to banks in India and abroad. These banks have declared Bilcare as a non-performing asset (NPA)," another source said.

The SFIO may also investigate the role of the statutory auditor in this case.

Source: Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more